These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 8335040)

  • 21. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
    Abdel-Rahman SM; Kauffman RE
    Annu Rev Pharmacol Toxicol; 2004; 44():111-36. PubMed ID: 14744241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.
    Cavero I
    Expert Opin Drug Saf; 2007 Jul; 6(4):465-71. PubMed ID: 17688390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding clinical applications of population pharmacodynamic modelling.
    Minto C; Schnider T
    Br J Clin Pharmacol; 1998 Oct; 46(4):321-33. PubMed ID: 9803979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned.
    La Gamba F; Jacobs T; Geys H; Jaki T; Serroyen J; Ursino M; Russu A; Faes C
    Pharm Stat; 2019 Jul; 18(4):486-506. PubMed ID: 30932327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.
    Zhu P; Sy SKB; Skerjanec A
    AAPS J; 2018 Mar; 20(2):40. PubMed ID: 29516330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics-pharmacodynamics during drug development--an example from Servier: ivabradine.
    Laveille C; Jochemsen R
    Therapie; 2004; 59(2):173-7. PubMed ID: 15359608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population modelling in drug development.
    Sheiner L; Wakefield J
    Stat Methods Med Res; 1999 Sep; 8(3):183-93. PubMed ID: 10636334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodological issues in pharmacokinetic-pharmacodynamic modelling.
    Bellissant E; Sébille V; Paintaud G
    Clin Pharmacokinet; 1998 Aug; 35(2):151-66. PubMed ID: 9739481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
    Toutain PL; Lees P
    J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein.
    Marshall S; Macintyre F; James I; Krams M; Jonsson NE
    Clin Pharmacokinet; 2006; 45(2):177-97. PubMed ID: 16485916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis.
    Gobburu JV; Chen EP
    J Pharm Sci; 1996 May; 85(5):505-10. PubMed ID: 8742942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.
    Danhof M; Alvan G; Dahl SG; Kuhlmann J; Paintaud G
    Pharm Res; 2005 Sep; 22(9):1432-7. PubMed ID: 16132354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.